Accuray (NASDAQ:ARAY) CEO Neve Stephen La Acquires 20,000 Shares

Accuray Incorporated (NASDAQ:ARAY) CEO Neve Stephen La bought 20,000 shares of Accuray stock in a transaction that occurred on Wednesday, November 19th. The stock was purchased at an average cost of $0.97 per share, for a total transaction of $19,400.00. Following the acquisition, the chief executive officer owned 20,000 shares of the company’s stock, valued at $19,400. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Accuray Stock Up 4.5%

NASDAQ ARAY traded up $0.04 on Thursday, hitting $0.97. 290,281 shares of the stock were exchanged, compared to its average volume of 819,554. Accuray Incorporated has a fifty-two week low of $0.91 and a fifty-two week high of $2.95. The company has a 50-day moving average price of $1.52 and a 200-day moving average price of $1.46. The company has a quick ratio of 0.92, a current ratio of 1.65 and a debt-to-equity ratio of 1.53. The company has a market cap of $109.49 million, a PE ratio of -47.70 and a beta of 1.39.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.13). The firm had revenue of $93.94 million for the quarter, compared to analysts’ expectations of $91.34 million. Accuray had a negative return on equity of 4.92% and a negative net margin of 0.35%. Accuray has set its FY 2026 guidance at EPS. Sell-side analysts anticipate that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Accuray

Institutional investors have recently modified their holdings of the business. Heartland Advisors Inc. boosted its stake in Accuray by 11.8% during the 1st quarter. Heartland Advisors Inc. now owns 4,274,750 shares of the medical equipment provider’s stock worth $7,652,000 after purchasing an additional 450,000 shares during the period. Mackenzie Financial Corp boosted its stake in shares of Accuray by 168.8% during the first quarter. Mackenzie Financial Corp now owns 733,347 shares of the medical equipment provider’s stock worth $1,313,000 after buying an additional 460,501 shares during the period. XTX Topco Ltd increased its position in Accuray by 130.2% in the 1st quarter. XTX Topco Ltd now owns 126,129 shares of the medical equipment provider’s stock valued at $226,000 after acquiring an additional 71,330 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Accuray by 5.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 278,384 shares of the medical equipment provider’s stock valued at $498,000 after acquiring an additional 14,649 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in Accuray by 44.0% during the 1st quarter. Deutsche Bank AG now owns 60,606 shares of the medical equipment provider’s stock valued at $108,000 after acquiring an additional 18,526 shares during the last quarter. 64.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ARAY. Weiss Ratings reissued a “sell (d-)” rating on shares of Accuray in a research report on Thursday, November 13th. Wall Street Zen downgraded shares of Accuray from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, BTIG Research lowered their target price on shares of Accuray from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 6th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.00.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.